Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2–experienced individuals
Marie I. Samanovic, Amber Cornelius, Sophie L. Gray-Gaillard, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 631
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet, Yousra Kherabi, Conor-James MacDonald, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 202-221
Open Access | Times Cited: 830
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
Sokratis A. Apostolidis, Mihir Kakara, Mark M. Painter, et al.
Nature Medicine (2021) Vol. 27, Iss. 11, pp. 1990-2001
Open Access | Times Cited: 481
Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination
Mark M. Painter, Divij Mathew, Rishi R. Goel, et al.
Immunity (2021) Vol. 54, Iss. 9, pp. 2133-2142.e3
Open Access | Times Cited: 433
The germinal centre B cell response to SARS-CoV-2
Brian J. Laidlaw, Ali H. Ellebedy
Nature reviews. Immunology (2021) Vol. 22, Iss. 1, pp. 7-18
Open Access | Times Cited: 217
mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants
Aurélien Sokal, Giovanna Barba–Spaeth, I. Fernández, et al.
Immunity (2021) Vol. 54, Iss. 12, pp. 2893-2907.e5
Open Access | Times Cited: 127
Mucosal immunity: The missing link in comprehending SARS-CoV-2 infection and transmission
Michael W. Russell, Jiří Městecký
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 78
mRNA Vaccines against SARS-CoV-2: Advantages and Caveats
Miriam Echaide, Luisa Chocarro, Ana Bocanegra, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5944-5944
Open Access | Times Cited: 53
Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals
Daniel Lozano‐Ojalvo, Carmen Cámara, Eduardo López‐Granados, et al.
Cell Reports (2021) Vol. 36, Iss. 8, pp. 109570-109570
Open Access | Times Cited: 99
Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine
Annalisa Ciabattini, G Pastore, Fabio Fiorino, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 99
T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses
Elahe Aleebrahim‐Dehkordi, Bahareh Molavi, Melika Mokhtari, et al.
Transplant Immunology (2021) Vol. 70, pp. 101495-101495
Open Access | Times Cited: 93
Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers
Gemma Moncunill, Ruth Aguilar, Marta Ribes, et al.
EBioMedicine (2022) Vol. 75, pp. 103805-103805
Open Access | Times Cited: 67
Increased Interleukin 18-Dependent Immune Responses Are Associated With Myopericarditis After COVID-19 mRNA Vaccination
Taejoon Won, Nisha A. Gilotra, Megan Kay Wood, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 42
Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections
Salomé Desmecht, Aleksandr Tashkeev, Majdouline El Moussaoui, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 41
COVID‐19 and plasma cells: Is there long‐lived protection?*
Doan C. Nguyen, Pedro A. Lamothe, Matthew C. Woodruff, et al.
Immunological Reviews (2022) Vol. 309, Iss. 1, pp. 40-63
Open Access | Times Cited: 41
Influence of age, gender, previous SARS-CoV-2 infection, and pre-existing diseases in antibody response after COVID-19 vaccination: A review
Maria da Conceição Rodrigues Fernandes, Germana Silva Vasconcelos, Amanda Campelo Lima de Melo, et al.
Molecular Immunology (2023) Vol. 156, pp. 148-155
Open Access | Times Cited: 34
COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign
M. Nathaniel Mead, Stephanie Seneff, Russ Wolfinger, et al.
Cureus (2024)
Open Access | Times Cited: 13
Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?
Giuseppe Lippi, Brandon Michael Henry, Mario Plebani
Diagnostics (2021) Vol. 11, Iss. 6, pp. 941-941
Open Access | Times Cited: 51
Longitudinal Analysis Reveals Distinct Antibody and Memory B Cell Responses in SARS-CoV2 Naïve and Recovered Individuals Following mRNA Vaccination
Rishi R. Goel, Sokratis A. Apostolidis, Mark M. Painter, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 42
BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
Abbass Darwich, Chiara Pozzi, Giulia Fornasa, et al.
EMBO Molecular Medicine (2022) Vol. 14, Iss. 5
Open Access | Times Cited: 34
mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients
Elena Azzolini, Chiara Pozzi, Luca Germagnoli, et al.
Life Science Alliance (2022) Vol. 5, Iss. 6, pp. e202201381-e202201381
Open Access | Times Cited: 33
Vaccination strategies and transmission of COVID-19: Evidence across advanced countries
Dongwoo Kim, Young Jun Lee
Journal of Health Economics (2022) Vol. 82, pp. 102589-102589
Open Access | Times Cited: 29
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial
Rolando Ochoa-Azze, Arturo Chang Monteagudo, Yanet Climent-Ruíz, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 8, pp. 785-795
Open Access | Times Cited: 28
The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses
Konstantin Föhse, Büsra Geckin, Martijn Zoodsma, et al.
Clinical Immunology (2023) Vol. 255, pp. 109762-109762
Open Access | Times Cited: 21
Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges
Bryce M. Warner, Jacob G. E. Yates, Robert Vendramelli, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
SARS‐CoV‐2 vaccination in solid‐organ transplant recipients: What the clinician needs to know
Maddalena Giannella, Lígia Câmera Pierrotti, Ilkka Helanterä, et al.
Transplant International (2021) Vol. 34, Iss. 10, pp. 1776-1788
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top